On November 1, 2021 Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) ("Checkmate"), a clinical stage biotechnology company focused on developing proprietary technology to harness the power of the immune system to combat cancer, reported that final clinical data from the Phase 1b study, CMP-001-001, of vidutolimod, an advanced generation Toll-like receptor 9 (TLR9) agonist, in combination with pembrolizumab or as a monotherapy will be presented at The Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 36th Annual Meeting to be held in person and virtually November 10-14, 2021 (Press release, Checkmate Pharmaceuticals, NOV 1, 2021, View Source [SID1234594030]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Presentation Details:
Title: Final analysis: phase 1b study investigating intratumoral injection of Toll-like receptor 9 agonist vidutolimod ± pembrolizumab in patients with PD-1 blockade–refractory melanoma
Presenting Author: John M. Kirkwood
Abstract #: 16269
ePoster #: 950
Location: Virtual Poster Hall Exhibit, November 12, 7:00am – 8:30pm ET